Skip to main content
SpringerLink
Log in

Bone Disease in Chronic Renal Failure

  • Chapter
Calcium in Internal Medicine

  • 192 Accesses

Abstract

Changes in mineral metabolism associated with progressive renal failure bring about disturbances of bone metabolism. Metabolic bone disease induced by chronic renal failure has been called renal bone disease or renal osteodystrophy. Some therapeutic interventions to this abnormal mineral metabolism also contribute to the development of bone disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Coburn JW. Renal osteodystrophy. Kidney Int. 1980;17:677–23.

    Article  PubMed  CAS  Google Scholar 

  2. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75: 145–50.

    Article  PubMed  CAS  Google Scholar 

  3. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG etal. Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function. Kidney Int 1993;44:860–66.

    Article  PubMed  CAS  Google Scholar 

  4. Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, Takagi H. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 1995;44 Suppl 1: S42–7.

    PubMed  Google Scholar 

  5. Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 1996;5:336–41.

    Article  PubMed  CAS  Google Scholar 

  6. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047–53.

    Article  PubMed  CAS  Google Scholar 

  7. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999;55:1375–83.

    Article  PubMed  CAS  Google Scholar 

  8. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ etal. p21WAF1 and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001;59:855–65.

    Article  PubMed  CAS  Google Scholar 

  9. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxy- vitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436–43.

    Article  PubMed  CAS  Google Scholar 

  10. Patel SR, Koenig RJ, Hsu CH. Effect of Schiff base formation on the function of the calcitriol receptor. Kidney Int 1996;50:1539–45.

    Article  PubMed  CAS  Google Scholar 

  11. Kinugasa E, Akizawa T, Koshikawa S. Parathyroid Function in end-stage renal failure. J Bone Mineral Met 1993; 11 (supp1):53–8.

    Article  Google Scholar 

  12. Goodman WG, Veldhuis JD, Belin TR, Van Herle AJ, Juppner H, Salusky IB. Calcium sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2765–72.

    Article  PubMed  CAS  Google Scholar 

  13. Akizawa T, Fukagawa M. Modulation of parathyroid cell function by calcium ion in health and uremia. Am J Med Sci 1999;317:358–62.

    Article  PubMed  CAS  Google Scholar 

  14. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J etal. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996;270:F454–60.

    PubMed  CAS  Google Scholar 

  15. Kifor O, Moore Jr FD, Wang P, Goldstein M, Vassilev P, Kifor I etal. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598–606.

    Article  PubMed  CAS  Google Scholar 

  16. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E etal. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328–36.

    Article  PubMed  CAS  Google Scholar 

  17. Brown A J, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999;55:1284–92.

    CAS  Google Scholar 

  18. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres etal. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996;11:970–6.

    Article  PubMed  CAS  Google Scholar 

  19. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534–40.

    CAS  Google Scholar 

  20. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez Cruz L etal. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9:1845–52.

    CAS  Google Scholar 

  21. Hernandez A, Concepcion MT, Rodriguez M, Salido E, Torres A. High phosphorus diet increases pre-proPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int 1996;50:1872–8.

    Article  PubMed  CAS  Google Scholar 

  22. de Francisco AL, Cobo MA, Setien MA, Rodrigo E, Fresnedo GF, Unzueta MT etal. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int 1998;54:2140–5.

    Article  PubMed  Google Scholar 

  23. Almaden Y, Canalejo A, Ballesteros E, Anon G, Rodriguez M. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 2000;11:1712–8.

    PubMed  CAS  Google Scholar 

  24. Yokoyama K, Shigematsu T, Tsukada T, Ogura Y, Takemoto F, Hara S etal. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int 1998;53:454–8.

    Article  PubMed  CAS  Google Scholar 

  25. Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis 1998;32:464–9.

    Article  PubMed  CAS  Google Scholar 

  26. Yano S, Sugimoto T, Kanzawa M, Tsukamoto T, Hattori T, Hattori S etal. Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in hemodialysis patients. Nephron 2000;85:317–23.

    Article  PubMed  CAS  Google Scholar 

  27. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicchi P, Bandini S etal. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993;76:139–44.

    Article  PubMed  CAS  Google Scholar 

  28. Canalejo A, Almaden Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM et al. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol 2000;11:1865–72.

    PubMed  CAS  Google Scholar 

  29. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A et al. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 2000;57:437–45.

    Article  PubMed  CAS  Google Scholar 

  30. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478–83.

    Article  PubMed  CAS  Google Scholar 

  31. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium Х phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607–17.

    Article  PubMed  CAS  Google Scholar 

  32. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35:1226–37.

    Article  PubMed  CAS  Google Scholar 

  33. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium Х phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907–14.

    Article  PubMed  CAS  Google Scholar 

  34. Slatopolsky EA, Burke SK, Dillon MA. Renagel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299–307.

    Article  CAS  Google Scholar 

  35. Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000;54:334–41.

    PubMed  CAS  Google Scholar 

  36. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136–43.

    Article  PubMed  CAS  Google Scholar 

  37. Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T etal. The oral 1,25-dihydroxy- vitamin D3 pulse therapy in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23–8.

    Article  PubMed  CAS  Google Scholar 

  38. Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994;20:97–102.

    PubMed  CAS  Google Scholar 

  39. Akizawa T, Fukagawa M, Koshikawa S, Kurokawa K. Recent progress in management of secondary hyperparathyroidism of chronic renal failure. Curr Opin Nephrol Hypertens 1993;2:558–65.

    Article  PubMed  CAS  Google Scholar 

  40. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxy- vitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427–32.

    PubMed  CAS  Google Scholar 

  41. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analog: 19-nor-l,25-dihydroxyvita- min D2. Am J Kidney Dis 1998;32(Suppl 2):S48–54.

    Article  PubMed  CAS  Google Scholar 

  42. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor- 1,25(OH)2D2 decreases with duration of treatment. J Am Soc Nephrol 2000;11:2088–94.

    PubMed  CAS  Google Scholar 

  43. Holliday LS, Gluck SL, Slatopolsky E, Brown AJ. 1,25-Dihydroxy-19-nor-vitamin D2, a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol 2000;11:1857–64.

    PubMed  CAS  Google Scholar 

  44. Tan Jr AU, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC etal. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317–23.

    Article  PubMed  CAS  Google Scholar 

  45. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991;39:874–81.

    Article  PubMed  CAS  Google Scholar 

  46. Kubrusly M, Gagne ER, Urena P, Hanrotel C, Chabanis S, Lacour B etal. Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993;44:551–6.

    Article  PubMed  CAS  Google Scholar 

  47. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38(Suppl 1):S147–51.

    Article  PubMed  CAS  Google Scholar 

  48. Denda M, Finch JL, Brown AJ, Nishii Y, Kubodera N, Slatopolsky E. 1,25-Dihydroxyvitamin D3 and 22- oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34–9.

    Article  PubMed  CAS  Google Scholar 

  49. Ichikawa F, Hirata M, Endo K, Katsumata K, Ohkawa H, Kubodera N et al. Attenuated up-regulation of vitamin D-dependent calcium-binding proteins by 22-oxa-l, 25-dihydroxyvitamin D3 in uremic rats. A possible mechanism for less-calcemic action. Nephrology 1998;4:391–5.

    CAS  Google Scholar 

  50. Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S etal. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999; 19: 1049–55.

    PubMed  CAS  Google Scholar 

  51. Morii H, Ogura Y, Koshikawa S, Mimura N, Suzuki M, Kurokawa K et al. Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyper-parathyroidism. J Bone Mineral Metab 1998;16:34–43.

    Article  CAS  Google Scholar 

  52. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998;32:238–46.

    Article  PubMed  CAS  Google Scholar 

  53. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000;57:50–8.

    Article  PubMed  CAS  Google Scholar 

  54. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998;53:448–53.

    Article  PubMed  CAS  Google Scholar 

  55. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998;53:223–7.

    CAS  Google Scholar 

  56. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436–45.

    Article  PubMed  CAS  Google Scholar 

  57. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994;46:1110–17.

    Article  PubMed  CAS  Google Scholar 

  58. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kurokawa K. Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients - the Japanese strategy. Nephrol Dial Transplant 1999;14:2574–7.

    Article  PubMed  CAS  Google Scholar 

  59. Kitaoka M, Fukagawa M, Kurokawa K. Direct injection of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995;1:563–8.

    Article  CAS  Google Scholar 

  60. Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091–9.

    Article  PubMed  CAS  Google Scholar 

  61. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K. Medical and surgical aspects of parathyroidectomy. Kidney Int 1999;73(Suppl):S65–9.

    Article  CAS  Google Scholar 

  62. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47:1434–42.

    Article  PubMed  CAS  Google Scholar 

  63. Akizawa T, Kinugasa E, Akiba T, Tsukamoto Y, Kurokawa K. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int 1997;62(Suppl):S72–4.

    CAS  Google Scholar 

  64. Smans KA, D’Haese PC, Van Landeghem GF, Andries LJ, Lamberts LV, Hendy GN et al. Transferrin- mediated uptake of aluminium by human parathyroid cells results in reduced parathyroid hormone secretion. Nephrol Dial Transplant 2000;15:1328–36.

    Article  PubMed  CAS  Google Scholar 

  65. Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens 2000;9:363–7.

    Article  PubMed  CAS  Google Scholar 

  66. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160–6.

    Article  PubMed  CAS  Google Scholar 

  67. Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis 1996;28:924–30.

    Article  PubMed  CAS  Google Scholar 

  68. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287–93.

    Article  PubMed  CAS  Google Scholar 

  69. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000;58:1440–9.

    Article  PubMed  CAS  Google Scholar 

  70. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753–61.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. T. Akizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Kinugasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2nd Department of Internal Medicine, Osaka City University Medical School, 1-4-3 Asahi-machi, 545-8585, Abeno-ku Osaka, Japan

    Hirotoshi Morii MD, PhD (Professor Emeritus) & Yoshiki Nishizawa MD, PhD (Professor Emeritus) & 

  2. Division of Nephrololgy Raulston Memorial Research Building, Room 104 Keck School of Medicine, University of Southern California, 2025 Zonal Avenue, 90033, Los Angeles, CA, USA

    Shaul G. Massry MD (Professor of Medicine) (Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag London Limited

About this chapter

Cite this chapter

Akizawa, T., Kinugasa, E. (2002). Bone Disease in Chronic Renal Failure. In: Morii, H., Nishizawa, Y., Massry, S.G. (eds) Calcium in Internal Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-0667-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-0667-8_20

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1173-3

  • Online ISBN: 978-1-4471-0667-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation